OnabotulinumtoxinA Improves Sleep Quality in Patients with Chronic Migraine: A Prospective Real-World Study.

months of treatment. Researchers found that sleep quality improved significantly in patients after receiving OBT-A. Specifically, 63% of patients reported better sleep after three months. Patients also experienced fewer migraine days and less headache severity. These findings suggest that OBT-A not only helps with migraines but also enhances sleep. Improved sleep quality can lead to better overall health and daily functioning. This study highlights the importance of treating both migraines and sleep issues together. Future research should explore how OBT-A affects sleep in different populations. Overall, this study offers hope for chronic migraine patients struggling with sleep problems. Effective treatments like OBT-A can improve both migraine symptoms and sleep quality for many individuals. Clinical relevance: This study indicates that OBT-A may help improve sleep quality in chronic migraine patients, potentially enhancing their overall well-being and treatment outcomes.